Makpime T 250mg/31.25mg Injection
Marketer
Makcur Laboratories Ltd.
Salt Composition
Cefepime (250mg) + Tazobactum (31.25mg)
Overview Makpime T 250mg/31.25mg Injection
Combiflox 250mg/31.25mg Injection, a dual-antibiotic formulation, combats diverse bacterial infections by inhibiting microbial proliferation. Administration must be solely under medical guidance. Complete the prescribed treatment regimen, regardless of symptom improvement. Commonly reported side effects include gastrointestinal upset (nausea, vomiting, diarrhea), skin reactions (rashes), and localized injection site inflammation (redness, swelling, pain), typically resolving spontaneously. However, worsening side effects necessitate immediate medical consultation. Seek immediate emergency care for allergic reactions (skin rashes, itching, swelling, respiratory distress). Disclose all current medications to your physician prior to commencing treatment. Pregnant or lactating individuals require prior medical consultation. Alcohol consumption should be avoided due to potential increased drowsiness. While generally non-impairing, driving should be avoided if drowsiness or dizziness occurs.
Primary Ingredients of Makpime T 250mg/31.25mg Injection
The provided text is "undefined," which cannot be rephrased while maintaining meaning and intent. There is no text to rewrite.
Uses of Makpime T 250mg/31.25mg Injection
Infections caused by bacteria
Major Benefits of Makpime T 250mg/31.25mg Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Makpime T 250mg/31.25mg Injection:
- Diarrhea
- Increased white blood cell count (eosinophils)
- Injection site phlebitis
- Skin rash
- Increased liver enzymes
- Positive Coombs test
How to use Makpime T 250mg/31.25mg Injection:
The medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
How Makpime T 250mg/31.25mg Injection works:
Makpime T Injection, containing 250mg Cefepime and 31.25mg Tazobactum, combines an antibiotic with a beta-lactamase inhibitor. Cefepime's antibacterial action disrupts bacterial cell wall synthesis, crucial for bacterial viability. Tazobactum counteracts bacterial enzymes that would otherwise neutralize Cefepime, thereby broadening Cefepime's effectiveness and overcoming bacterial resistance.
SAFETY ADVICE
AlcoholCAUTION
Exercise caution when using Makpime T 250mg/31.25mg Injection concurrently with alcohol. Seek medical advice before combining them.
PregnancySAFE IF PRESCRIBED
The injectable medication Makpime T, 250mg/31.25mg, is typically deemed safe for use during gestation. Preclinical trials in animals revealed minimal or no negative impact on fetal development; however, corresponding data from human trials remain scarce.
Breast feedingSAFE IF PRESCRIBED
The injectable medication Makpime T (250mg/31.25mg) is considered safe for breastfeeding mothers. Research in humans indicates minimal drug transfer to breast milk, posing no apparent risk to the infant.
DrivingUNSAFE
Following administration of Makpime T 250mg/31.25mg Injection, temporary blurred vision may occur. Refrain from driving until your vision has returned to normal.
KidneyCAUTION
Patients with kidney impairment should use Makpime T 250mg/31.25mg Injection cautiously. Dosage modification may be necessary; physician consultation is advised.
LiverSAFE IF PRESCRIBED
The use of Makpime T 250mg/31.25mg Injection in patients with hepatic impairment is likely safe. Available evidence indicates dose modification may be unnecessary; however, physician consultation is recommended.
What if you forget to take Makpime T 250mg/31.25mg Injection :
Should you inadvertently omit a scheduled dose of Makpime T 250mg/31.25mg Injection, seek guidance from your physician.
Facts to Know About Makpime T 250mg/31.25mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Antimicrobial Agents |
3,018 People bought this recently